The shares with the highest 52-week returns are mostly volatile bulletin board stocks.

Is the steep premium too much for a biotech with no products on the market? Corixa's 18% drop suggests some investors think so.

The all-stock transaction is expected to be completed in December.

A cancer center the company has worked with did not notify the agency of tests, the FDA says.

'No clinical trials sponsored by Immunomedics have been halted because of adverse events or deaths,' the CEO says.

Target brings in a famous partner to expand designs.

Chick-fil-A is offering more variety in a new concept.

The Indian tycoon and his empire are facing allegations of fraud by an American short-seller. Their answer does not convince investors for the moment.

The billionaire had proposed a controversial plan to end the Russia-Ukraine conflict, which now has lasted nearly a year.